InnoCom's investment fund offers a unique opportunity to contribute to critical medical advancements, with a current portfolio of thirteen companies that have invested over $165 million in solutions for cancer, COVID-19, and more. The fund is projected to deliver substantial returns, with outside experts estimating a six-year valuation of $350 billion and very attractive potential investor returns as well. InnoCom's Principals, experienced C-level executives, actively support each portfolio company, enabling them to focus more specifically on scientific innovation and sustainable product realization. The fund's risk is mitigated by its diversity, hands on Strategic and Operational care and an early commercialization strategy bolstered by strong ties with the veterinary community on the way to human clinical approval worldwide.
Company Details
- Employees
- 3
- Founded
- -
- Address
- San Francisco, Us
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- https://www.innocombio.com
- HQ
- San Francisco
Innocom Bio Equities Questions
Innocom Bio Equities's website is https://www.innocombio.com
Innocom Bio Equities's LinkedIn profile is https://www.linkedin.com/company/innocom-bio-equities
Innocom Bio Equities has
3 employees.
View email and phone details for 3
employees at Innocom Bio Equities.
Innocom Bio Equities's industry is
Venture Capital and Private Equity Principals
Innocom Bio Equities's top competitors are
Socal Safe Company,
Earthone,
Quincy Bioscience,
Dermoscent®,
Defy Co.labs,
Aratana Therapeutics Inc.,
Jlb Associates,
Rubicon,
Imcare Biotech,
Inceptiv.
Innocom Bio Equities's categories are Venture Capital and Private Equity Principals
Innocom Bio Equities's founding year is 2020
